FDA approves first oral blood thinning medicines for children


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
With the approval of Pradaxa, a blood-clotting medicine, pediatric patients have a good therapeutic option to treat and prevent potentially deadly blood clots.

The thrombotic issue is emerging in this pandemic causing a blood clotting problem which is considered as a complication. Blood clotting is a universal phenomenon and it is a protective mechanism in external cellular and tissue injury. But, due to pandemics, thrombosis or blood clot is considered a complication that needs special attention. There are some presentations of blood clotting showing up in COVID-19 patients as a complication. The autopsy report of the COVID19 patients has revealed clots in the small vessels of the lung, liver, heart, kidney which are responsible for stroke and heart problems. 

D- dimer test for COVID 

We have seen people suffering from COVID having thrombotic issues. Many doctors are coming forward and prescribing D-dimer tests to COVID patients to exclude the complication of thrombosis from this pandemic. Critical COVID patients are reported to have high levels of blood clotting or elevated levels of D- dimer. 

Research regarding the blood clots this pandemic 

Scientists are keen on finding out why blood clots form as a post COVID complication. According to a study from the Royal College of Surgeons in Ireland University of Medicines and health science, research is going on to know the main reason behind this blood clot complication. 

The study has shown some evidence that the von Willebrand Factor (vWF) is severely disrupted in critically ill COVID 19 patients. vWF factor is a protein that causes and promotes blood clots along with an enzyme ADAMTS13 which regulates clotting. The researchers took and examined the samples from COVID-19 patients and compared it with the NON-COVID patients. The blood of COVID patients had higher levels of pro- clotting factors which is von Willebrand Factor (vWF) and lower levels of anti-clotting enzymes. As per the research-based study, blood clotting is a major cause of death in COVID19 patients. 

Blood clots are a serious problem seen in children 

Blood clots may be a critical problem in children making them difficult to deal with. Apart from COVID19, any cases of cancer, congenital heart disease, hemophilia, or venous thromboembolism may lead to many complications. This may require admitting the child to the Intensive Care Unit (ICU). The complications of a blood clot in children are as follows: 

Swelling  Discomfort at the clot  Chest pain  Lung damage  Cardiac problems Or even death 

FDA approves Pradaxa 

Pradaxa is the first approved blood-thinning medication that children can take by mouth. Apart from this, there was an injectable that was approved earlier for children for blood clot treatment. The FDA is committed to taking care of the patients, especially children of this COVID pandemic. With the approval of Pradaxa, a blood-clotting medicine, pediatric patients have a good therapeutic option to treat and prevent potentially deadly blood clots. The safety and efficacy of treating blood clots in the pediatric population is evaluated in 267 children under the age of 18 years who were diagnosed with blood clotting issues. The FDA has granted approval of Pradaxa to Boehringer Ingelheim Pharmaceuticals Inc. 

Tags : #FDA #bloodclottingmedicine #thrombosis #bloodclot #Pradaxa #COVID #pandemic #medicircle #myhealth

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026